Increased SARS-CoV-2-related hospitalization and mortality in rheumatoid arthritis patients receiving rituximab therapy-a monocentric retrospective study.

IF 4.5 2区医学 Q2 IMMUNOLOGY

Journal of Microbiology Immunology and Infection Pub Date : 2025-01-28 DOI:10.1016/j.jmii.2025.01.004

Chrong-Reen Wang, Chih-Hui Hsu, Wei-Chieh Lin

引用次数: 0

Abstract

From 2022 April to 2024 August, retrospective analyses by multivariable logistic regression were conducted in 341 rheumatoid arthritis patients receiving rituximab (RTX), tofacitinib (TOF) or disease-modifying-anti-rheumatic drug (DMARD) alone therapy. Compared to DMARD alone or TOF treatment, RTX therapy had increased adjusted odds ratios of SARS-CoV-2-related hospitalization, pneumonia and mortality.

查看原文本刊更多论文

2022 年 4 月至 2024 年 8 月，研究人员通过多变量逻辑回归对 341 名接受利妥昔单抗（RTX）、托法替尼（TOF）或单独使用疾病修饰抗风湿药（DMARD）治疗的类风湿性关节炎患者进行了回顾性分析。与单纯 DMARD 或 TOF 治疗相比，RTX 治疗增加了与 SARS-CoV-2 相关的住院、肺炎和死亡率的调整后几率比。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Microbiology Immunology and Infection IMMUNOLOGY-INFECTIOUS DISEASES

CiteScore

15.90

自引率

5.40%

发文量

159

审稿时长

67 days

期刊介绍： Journal of Microbiology Immunology and Infection is an open access journal, committed to disseminating information on the latest trends and advances in microbiology, immunology, infectious diseases and parasitology. Article types considered include perspectives, review articles, original articles, brief reports and correspondence. With the aim of promoting effective and accurate scientific information, an expert panel of referees constitutes the backbone of the peer-review process in evaluating the quality and content of manuscripts submitted for publication.